G1 Therapeutics, a clinical-stage biotech developing novel therapeutics for cancer, filed on Thursday with the SEC to raise up to $115 million in an initial public offering.
The Research Triangle Park, NC-based company was founded in 2008 and it plans to list on the Nasdaq under the symbol GTHX. G1 Therapeutics filed confidentially on February 5, 2017. J.P. Morgan, Cowen & Company, Needham & Co. and Wedbush Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
